---
search:
  boost: 2 
---

# Anti-Migraine Agents, Cluster Headache

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                                    | Generic Name                                              |         Quantity          |        Time (Days)        |
| :------------------------------------------- | :-------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Verapamil <sup>QL</sup>                      | Verapamil HCI Tab (all strengths)                         |            408            |            102            |
| Verapamil CR (generic Calan) <sup>QL</sup>   | Verapamil HCI CR Tab (all strengths)                      |            204            |            102            |
| Verapamil ER (generic Verelan) <sup>QL</sup> | Verapamil HCI SR Cap (all strengths excl 200 MG & 240 MG) |            102            |            102            |
| Verapamil ER (generic Verelan) <sup>QL</sup> | Verapamil HCI SR Cap 200 MG & 240 MG                      |            204            |            102            |
| Verapamil (generic Verelan PM) <sup>QL</sup> | Verapamil HCI SR Cap (all strengths)                      | Determined pursuant to PA | Determined pursuant to PA |

### Non-Preferred

| Non-Preferred          | Generic Name                                                 |         Quantity          |        Time (Days)        |
| :--------------------- | :----------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Emgality <sup>QL</sup> | Galcanezumab Subcutaneous Inj (all strengths & formulations) | Determined pursuant to PA | Determined pursuant to PA |

## Length of Authorizations

180 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **60 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Information

- An inadequate clinical response to verapamil is defined as a titration to at least 480mg daily

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - Emgality: 3 doses per 30 days (for initial loading dose only), then 1 dose per 30 days thereafter

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=27)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=14)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
